ADIPOQ and cancer: Consequently, a total of 11 studies [18–28] were enrolled in the meta-analysis investigating the relationships between LEP/LEPR/ADIPOQ/ADIPOR1/ADIPOR2 variants and total PCa risk (Table 1), and ten studies [19, 23, 29–36] were included in the pooled-review discussing these polymorphisms' impact on the aggressiveness of cancer (Table 2).